ATOSSA THERAPEUTICS, INC.
No enriched coverage for $ATOS in the last 7 days.
No SEC Form 4 filings for $ATOS in the last 30 days.
Atossa Genetics Inc. (NASDAQ:ATOS) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $6.33. The biotechnology company, focused on breast cancer therapeutics, currently trades around $0.65. Institutional ownership stands at approximately 12.74%, with notable recent increases from firms like Bank of America and Qube Research & Technologies.
Atossa Therapeutics (ATOS) has received Orphan Drug Designation from the FDA for its drug candidate, Z-endoxifen, for treating Duchenne muscular dystrophy. This designation is a significant step for the clinical-stage biopharmaceutical company, which focuses on unmet medical needs in oncology. Despite facing challenges in revenue growth and profitability, Atossa demonstrates strong financial health with no debt and high liquidity, suggesting resilience against potential setbacks.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
